| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 500mg | ||
| Other Sizes |
| Targets |
IC50: 35 nM (FAK)[1]
|
|---|---|
| ln Vitro |
FAK-IN-2 (compound 11w) exhibits significant anti-proliferation actions on cancer cell lines (0–5 μM; 72 hours) and a considerable degree of toxicity on normal cell lines [1]. In a dose-dependent manner, FAK-IN-2 (0–30 nM; 14 days) can significantly impact the clone generation of HCT-116 cells[1]. The migration of HCT116 cells is greatly inhibited by FAK-IN-2 (10-500 nM; 24 and 48 hours) in a dose-dependent manner[1]. The phosphorylation of FAK and its downstream proteins is inhibited by FAK-IN-2 (0.001-10 μM; 4 and 24 hours) through various pathways[1]. Apoptosis and a significant cell cycle arrest at the G2/M phase are caused by -2 (0.01-1 μM; 24 or 48 hours)[1]. .
|
| ln Vivo |
FAK-IN-2 (once daily for 16 days at 5 and 15 mg/kg) possesses strong anticancer activity in dose-dependent manner in model mice without causing appreciable harm.[1] Sprague-Dawley male rat FAK-IN-2 pharmacokinetic parameters[1]. PO (5 milligrams per kilogram) IV (5 mg/kg) (μg/L) 239.87 2965.27 Cmax T1/2 (h) 4.70 7.57 Clz (L/h/kg) Tmax (h) 1.44 0.08 9.92 2.19 (μg*h/L) AUC0-t 2439.06 F% 21.02% 512.75
|
| Cell Assay |
Cell Proliferation Assay
Cell Types: Hela, HCT116, MDA-MB-231, H9C2, L929, LO2, HEK293[1] Tested Tested Concentrations: 0-5 μM Incubation Duration: 72 hrs (hours) Experimental Results: demonstrated high anti-proliferation activities on cancer cell lines, as well as certain toxicity on normal cell lines. Western Blot Analysis Cell Types: HCT116 cells[1] Tested Tested Concentrations: 0.001, 0.01, 0.1, 1 and 10 μM Incubation Duration: 4 and 24 hrs (hours) Experimental Results: Inhibited the phosphorylation of FAK and its downstream proteins from multiple pathways. Cell Cycle Analysis Cell Types: HCT116 cells[1] Tested Tested Concentrations: 0.01, 0.05, 0.1 and 0.5 μM for 24 hrs (hours); 0.01, 0.05, 0.1, 0.3 and 1 μM for 48 hrs (hours) Incubation Duration: 24 and 48 hrs (hours) Experimental Results: Induced strong cell cycle arrest at the G2/M phase and apoptosis. |
| Animal Protocol |
Animal/Disease Models: Female Balb/C nu/nu (nude) mice (HCT116-injected)[1]
Doses: 5 and 15 mg/kg Route of Administration: 16 days; one time/day Experimental Results: Displayed potent antitumor effects in a dose-dependent manner without significant toxicity. |
| References |
[1]. Chen T, et al. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase. Bioorg Med Chem Lett. 2021;54:128433.
|
| Molecular Formula |
C28H31CLN8O3
|
|---|---|
| Molecular Weight |
563.05
|
| CAS # |
2872588-02-6
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7760 mL | 8.8802 mL | 17.7604 mL | |
| 5 mM | 0.3552 mL | 1.7760 mL | 3.5521 mL | |
| 10 mM | 0.1776 mL | 0.8880 mL | 1.7760 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
